source
- BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer studyThe companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.BioPharma Dive · 15d ago↗ source
- STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and moreBristol Myers Squibb reported that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trialSTAT · 15d ago↗ source
- Merck and Moderna’s mRNA melanoma vaccine cuts recurrence risk by 42% in Phase 3 trialA Phase 3 study of a personalized mRNA vaccine for melanoma, developed by Merck and Moderna, showed a substantial improvement in patient outcomes. Patients receiving the vaccine together with Merc…